Search by Drug Name or NDC
NDC 69238-1471-03 Erythromycin 250 mg/1 Details
Erythromycin 250 mg/1
Erythromycin is a ORAL TABLET, DELAYED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amneal Pharmaceuticals NY LLC. The primary component is ERYTHROMYCIN.
MedlinePlus Drug Summary
Erythromycin is used to treat certain infections caused by bacteria, such as infections of the respiratory tract, including bronchitis, pneumonia, Legionnaires' disease (a type of lung infection), and pertussis (whooping cough; a serious infection that can cause severe coughing); diphtheria (a serious infection in the throat); sexually transmitted diseases (STD), including syphilis; and ear, intestine, gynecological, urinary tract, and skin infections. It also is used to prevent recurrent rheumatic fever. Erythromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria. Antibiotics such as erythromycin will not work for colds, flu, or other viral infections. Taking antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.
Related Packages: 69238-1471-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Erythromycin
Product Information
| NDC | 69238-1471 |
|---|---|
| Product ID | 69238-1471_bb2561ee-b370-49e6-8115-e424f7b92db1 |
| Associated GPIs | 03100005000605 |
| GCN Sequence Number | 009263 |
| GCN Sequence Number Description | erythromycin base TABLET DR 250 MG ORAL |
| HIC3 | W1D |
| HIC3 Description | MACROLIDE ANTIBIOTICS |
| GCN | 40730 |
| HICL Sequence Number | 004022 |
| HICL Sequence Number Description | ERYTHROMYCIN BASE |
| Brand/Generic | Generic |
| Proprietary Name | Erythromycin |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Erythromycin |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, DELAYED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 250 |
| Active Ingredient Units | mg/1 |
| Substance Name | ERYTHROMYCIN |
| Labeler Name | Amneal Pharmaceuticals NY LLC |
| Pharmaceutical Class | Decreased Sebaceous Gland Activity [PE], Macrolide Antimicrobial [EPC], Macrolide [EPC], Macrolides [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210954 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 69238-1471-03 (69238147103)
| NDC Package Code | 69238-1471-3 |
|---|---|
| Billing NDC | 69238147103 |
| Package | 30 TABLET, DELAYED RELEASE in 1 BOTTLE (69238-1471-3) |
| Marketing Start Date | 2021-08-27 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 3.85913 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | ERYTHROMYCIN DR 250 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |